Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation

Circulation

Volumn 128, Issue 12, 2013, Pages 1298-1309

  Varbo, Anette ^a,b,c   Benn, Marianne ^a,b,c   Tybjærg Hansen, Anne ^a,b,c,d,e   Nordestgaard, Børge G ^a,b,c,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Copenhagen General Population Study ^*  (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

cardiovascular diseases; genetics; lipids; lipoproteins; risk factors

Indexed keywords

C REACTIVE PROTEIN; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REMNANT CHOLESTEROL; STATIN (PROTEIN); TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BODY HEIGHT; BODY MASS; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; NEPHELOMETRY; OBESITY; PLEIOTROPY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; GENETICS; LIPIDS; LIPOPROTEINS; RISK FACTORS;

ADULT; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; DENMARK; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; TRIGLYCERIDES;

EID: 84884284181     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003008     Document Type: Article

References (26)

1. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-436.
2. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826-1833.
3. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
4. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-288.
5. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644-1648
6. Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, Quiney J, Lewis B. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991;11:569-577.
7. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intimainner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
8. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-1163.
9. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
10. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjaerg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundstrom J, Wassertheil-Smoller S, Mellstrom D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A, Ljunggren O, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Holm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213.
11. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey Smith G, Timpson NJ. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012;9:e1001212.
12. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
14. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
15. Gotto AM Jr, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol. 2012;110:15A-26A.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
17. Narverud I, Ueland T, Nenseter MS, Retterstøl K, Telle-Hansen VH, Halvorsen B, Ose L, Aukrust P, Holven KB. Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor ? system and interleukin-10. Atherosclerosis. 2011;214:163-168.
18. Hovland A, Aagnes I, Brekke OL, Flage JH, Lappegård KT. No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. J Clin Lipidol. 2010;4:288-292.
19. Charakida M, Tousoulis D, Skoumas I, Pitsavos C, Vasiliadou C, Stefanadi E, Antoniades C, Latsios G, Siasos G, Stefanadis C. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204:532-537.
20. Ye ZX, Cheng HM, Chiou KR, Charng MJ. Relation of C-reactive protein and carotid intima media thickness in Taiwanese with familial hypercholesterolemia. Am J Cardiol. 2008;102:184-187.
21. Real JT, Martínez-Hervás S, García-García AB, Civera M, Pallardó FV, Ascaso JF, Viña JR, Chaves FJ, Carmena R. Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia. Eur J Clin Invest. 2010;40:89-94.
22. Guardamagna O, Abello F, Saracco P, Baracco V, Rolfo E, Pirro M. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. 2009;207:471-475.
23. Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG. Increased inflammatory markers in children with familial hypercholesterolaemia. Eur J Clin Invest. 2006;36:147-152.
24. Panz V, Immelman A, Paiker J, Pilcher G, Raal F. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord. 2012;10:351-357.
25. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36-47.
26. Davey Smith G, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through mendelian randomization. Ann Med. 2008;40:524-541.